AU2003248782A1 - Humanized anti-lymphotoxin beta receptor antibodies - Google Patents

Humanized anti-lymphotoxin beta receptor antibodies Download PDF

Info

Publication number
AU2003248782A1
AU2003248782A1 AU2003248782A AU2003248782A AU2003248782A1 AU 2003248782 A1 AU2003248782 A1 AU 2003248782A1 AU 2003248782 A AU2003248782 A AU 2003248782A AU 2003248782 A AU2003248782 A AU 2003248782A AU 2003248782 A1 AU2003248782 A1 AU 2003248782A1
Authority
AU
Australia
Prior art keywords
antibody
seq
light chain
heavy chain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003248782A
Other languages
English (en)
Inventor
Ellen Garber
Jose Saldanha
Kenneth Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Publication of AU2003248782A1 publication Critical patent/AU2003248782A1/en
Assigned to BIOGEN IDEC MA INC. reassignment BIOGEN IDEC MA INC. Amend patent request/document other than specification (104) Assignors: BIOGEN, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003248782A 2002-07-01 2003-07-01 Humanized anti-lymphotoxin beta receptor antibodies Abandoned AU2003248782A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39299302P 2002-07-01 2002-07-01
US60/392,993 2002-07-01
US41737202P 2002-10-09 2002-10-09
US60/417,372 2002-10-09
PCT/US2003/020762 WO2004002431A2 (en) 2002-07-01 2003-07-01 Humanized anti-lymphotoyin beta receptor antibodies

Publications (1)

Publication Number Publication Date
AU2003248782A1 true AU2003248782A1 (en) 2004-01-19

Family

ID=30003289

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003248782A Abandoned AU2003248782A1 (en) 2002-07-01 2003-07-01 Humanized anti-lymphotoxin beta receptor antibodies

Country Status (10)

Country Link
US (1) US7429645B2 (https=)
EP (1) EP1539793A4 (https=)
JP (1) JP2005532051A (https=)
CN (1) CN1678625A (https=)
AR (1) AR040367A1 (https=)
AU (1) AU2003248782A1 (https=)
CA (1) CA2491480A1 (https=)
NZ (1) NZ537965A (https=)
TW (1) TW200416044A (https=)
WO (1) WO2004002431A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2344049C (en) * 1998-10-09 2009-12-15 Biogen, Inc. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
MXPA03003144A (es) * 2000-10-13 2004-12-06 Biogen Inc Anticuerpos humanizados anti-lt-??-r.
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
JP2006513225A (ja) * 2002-12-20 2006-04-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 化学療法剤と組み合わせたリンホトキシンβ受容体因子
CA2529945A1 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
JP2005241389A (ja) * 2004-02-25 2005-09-08 Ochiyanomizu Jiyoshi Univ 蛍光標識糖鎖の特異的固定化試薬および固定化方法
AU2005227322A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
KR20090078349A (ko) 2006-10-12 2009-07-17 제넨테크, 인크. 림포톡신-알파에 대한 항체
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
JP2010506955A (ja) * 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置
US20090074780A1 (en) 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
JP2012514458A (ja) * 2008-12-31 2012-06-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗リンホトキシン抗体
JP2013529076A (ja) 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｆｇｆｒ２抗体
TWI897855B (zh) * 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
CA3164226A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CR20240246A (es) * 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
WO2025012620A1 (en) 2023-07-07 2025-01-16 Mestag Therapeutics Ltd Binding constructs
EP4527851A1 (en) 2023-09-22 2025-03-26 Bayer Aktiengesellschaft Bispecific antibodies binding ltbr and lrrc15
WO2025172587A1 (en) 2024-02-16 2025-08-21 Mestag Therapeutics Ltd Binding constructs
WO2025172588A1 (en) 2024-02-16 2025-08-21 Mestag Therapeutics Ltd Bispecific constructs directed against fap and ltbr
WO2025221728A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992000329A1 (en) 1990-06-27 1992-01-09 Biogen, Inc. Surface complexed lymphotoxin
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69334224D1 (de) 1992-12-04 2008-07-17 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
CN1900116A (zh) * 1995-01-26 2007-01-24 拜奥根Idec马萨诸塞公司 抗－LT－β－R抗体、含有该抗体的药用组合物及其制药应用
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
ES2211035T3 (es) 1998-01-30 2004-07-01 Biogen, Inc. Tratamiento de linfomas foliculares usando inhibidores de la ruta de la linfotoxina (lt).
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
GB9809839D0 (en) * 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
MXPA03003144A (es) * 2000-10-13 2004-12-06 Biogen Inc Anticuerpos humanizados anti-lt-??-r.
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
JP2006513225A (ja) * 2002-12-20 2006-04-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 化学療法剤と組み合わせたリンホトキシンβ受容体因子
AU2005227322A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof

Also Published As

Publication number Publication date
CA2491480A1 (en) 2004-01-08
EP1539793A2 (en) 2005-06-15
CN1678625A (zh) 2005-10-05
EP1539793A4 (en) 2006-02-01
US20060222644A1 (en) 2006-10-05
NZ537965A (en) 2008-04-30
US7429645B2 (en) 2008-09-30
WO2004002431A2 (en) 2004-01-08
WO2004002431A3 (en) 2004-08-26
AR040367A1 (es) 2005-03-30
TW200416044A (en) 2004-09-01
JP2005532051A (ja) 2005-10-27

Similar Documents

Publication Publication Date Title
US7429645B2 (en) Humanized anti-lymphotoxin beta receptor antibodies
AU2002211747B2 (en) Humanized anti-LT-Beta-R antibodies
AU2002211747A1 (en) Humanized anti-LT-Beta-R antibodies
CA2981312C (en) Heavy chain constant regions with reduced binding to fc gamma receptors
KR101644674B1 (ko) Ｃｄ３７―결합 분자 및 이의 면역접합체
AU2008232409C1 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
CA2195557C (en) Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US20040006212A1 (en) Antibody and antibody fragments for inhibiting the growth of tumors
CA2619298A1 (en) Modified antigen binding molecules with altered cell signaling activity
CA2629147A1 (en) Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin
RU2770620C1 (ru) Связывающие молекулы, вызывающие клеточную активацию
US20030224001A1 (en) Antibody and antibody fragments for inhibiting the growth of tumors
JP2024519078A (ja) 抗ｃｅａ抗体及びその使用方法
US20040253234A1 (en) Humanized antibody against fibroblast growth factor-8 and antibody fragment thereof
TW202535956A (zh) 抗ＭＩＧＩＳ－α抗體及其使用方法
ZA200303347B (en) Humanized anti-LT-beta-R antibodies.
AU2013203712A1 (en) Binding Proteins, Including Antibodies, Antibody Derivatives And Antibody Fragments, That Specifically Bind CD154 And Uses Thereof
HK40110049A (zh) 对人和食蟹猴蛋白具有交叉反应性的抗cd3抗体

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ HUMANIZED ANTI-LYMPHOTOXIN BETA RECEPTOR ANTIBODIES

TC Change of applicant's name (sec. 104)

Owner name: BIOGEN IDEC MA INC.

Free format text: FORMER NAME: BIOGEN, INC.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application